Evidence map›Paper›PMID 32072633›Full record

ArticleBritish journal of pharmacology2020

Meprin-α (Mep1A) enhances TNF-α secretion by mast cells and aggravates abdominal aortic aneurysms.

Ran Gao, Duan Liu, Wenjun Guo, Weipeng Ge, Tianfei Fan, Bolun Li, Pan Gao, Bin Liu, Yuehong Zheng, Jing Wang

Open access · bronzeAbstract read
In one paragraph

Article in British journal of pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 16 citations in OpenAlex.

  1. Myeloid Cells in Abdominal Aortic Aneurysm.Current atherosclerosis reports · 2025
    Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Frontiers in cardiovascular medicine · 2022
    Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Ran GaoState Key Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, Department of Pathophysiology, Peking Union Medical College, Beijing, China.
Duan LiuPeking Union Medical College Hospital, Beijing, China.
Wenjun GuoState Key Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, Department of Pathophysiology, Peking Union Medical College, Beijing, China.
Weipeng GeState Key Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, Department of Pathophysiology, Peking Union Medical College, Beijing, China.
Tianfei FanState Key Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, Department of Pathophysiology, Peking Union Medical College, Beijing, China.
Bolun LiState Key Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, Department of Pathophysiology, Peking Union Medical College, Beijing, China.
Pan GaoDepartment of Geriatrics, Southwest Hospital, The First Affiliated Hospital to Army Medical University, Chongqing, China.
Bin LiuAab Cardiovascular Research Institute, University of Rochester, Rochester, USA.
Yuehong ZhengPeking Union Medical College Hospital, Beijing, China.
Jing WangState Key Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, Department of Pathophysiology, Peking Union Medical College, Beijing, China.ORCID 0000-0003-2410-5408
Chinese Academy of Medical Sciences & Peking Union Medical College · CNArmy Medical University · CNUniversity of Rochester · US

Funding

Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences 2016-I2M-1-006National Natural Science Foundation of China 81370007National Natural Science Foundation of China 81470579National Natural Science Foundation of China 81622008National Natural Science Foundation of China 91739107Open Research Funds of the State Key Laboratory of Genetic Engineering SKLGE-1607Thousand Young Talents Program of China
6 · The paper itself

Abstract

background and purposeAbdominal aorticaneurysm (AAA) rupture is mainly due to elastic lamina degradation. As a metalloendopeptidase, meprin-α (Mep1A) critically modulates the activity of proteins and inflammatory cytokines in various diseases. Here, we sought to investigate the functional role of Mep1A in AAA formation and rupture. EXPERIMENTAL APPROACH: AAA tissues were detected by using real-time PCR (RT-PCR), western blotting (WB), and immunohistochemistry. Further mechanistic studies used RT-PCR, WB, and enzyme-linked immunosorbent assays. KEY

resultsMep1A mediated AAA formation by regulating the mast cell (MC) secretion of TNF-α, which promoted matrix metalloproteinase (MMP) expression and apoptosis in smooth muscle cells (SMCs). Importantly, increased Mep1A expression was found in human AAA tissues and in angiotensin II-induced mouse AAA tissues. Mep1A deficiency reduced AAA formation and increased the survival rate of AAA mice. Pathological analysis showed that Mep1A deletion decreased elastic lamina degradation and SMC apoptosis in AAA tissues. Furthermore, Mep1A was expressed mainly in MCs, wherein it mediated TNF-α expression. Mep1A inhibitor actinonin significantly inhibited TNF-α secretion in MCs. TNF-α secreted by MCs enhanced MMP2 expression in SMCs and promoted SMC apoptosis. CONCLUSION AND IMPLICATIONS: Taken together, these data suggest that Mep1A may be vital in AAA pathophysiology by regulating TNF-α production by MCs. Knocking out Mep1A significantly decreased AAA diameter and improved AAA stability in mice. Therefore, Mep1A is a potential new therapeutic target in the development of AAA.

Indexed as

Aortic Aneurysm, AbdominalMast CellsMetalloendopeptidasesTumor Necrosis Factor-alphaAnimalsMatrix MetalloproteinasesMiceMatrix Metalloproteinasesmeprin AMetalloendopeptidasesTumor Necrosis Factor-alpha

Identifiers

PMID32072633
PMCPMC7236073
OpenAlexW3007263656

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.